The FLF CURE FL awards
Therapeutic development initiatives to accelerate advanced and translational research
FL is a disease that for most runs a course of moving from periods of remission into relapse and back again and most patients experience multiple relapses over the course of their disease which can run for years or decades. For a small number of patients, the disease progresses earlier, and they can face 5-year survival rates as low as 50%. But like many cancers FL is genetically not just one disease, so to find cures will require a range of therapies to help a range of people. This rests on finding the right drug to be provided to the right patient at the right time.
The FLF are launching a suite of initiatives aimed to make curative therapies available to FL patients as soon as possible. The first initiative is the Follicular Lymphoma Foundation CURE FL Awards – Curative Research to Eliminate Follicular Lymphoma, launched in early 2022.
2022 CURE FL Awards – a focussed new initiative
The FLF exists for one purpose – to lead new and determined efforts to find better treatments and cures for FL. We are the first charity in the world solely focusing on follicular lymphoma and we are dedicated to finding a cure – and fast.
In pursuit of this mission the FLF CURE FL Awards is a focused new funding initiative under leadership of FLF Chief Medical Officer Dr Mitchell Smith and FLF scientific advisor Dr Jonathan Simons developed with The Milken Institute Center for Strategic Philanthropy and with the input and involvement of a wide range of experts in the field.
On the 10th January 2022 we published a call for proposals for innovative projects focusing in areas of treatment we have identified as being the most likely to deliver rapid progress towards cure. The funding programme is being delivered by the Milken Institute Center for Strategic Philanthropy.
The FLF CURE FL Awards 2022 is focussing on work in two areas as the most likely currently to lead to curative therapies available to FL patients as soon as possible: cellular immunotherapy, CAR-T (chimeric antigen receptor T cells) and others, and also targeted therapies either as stand-alone treatments or in combination with other treatments.
The programme is designed to encourage creative approaches to examining how these therapies can best be targeted towards cure in FL. Criteria for assessment will include the potential of any work funded to go into a clinical trial or be applied directly to patient treatment in the near term. We encourage potential applicants to think creatively and about high risk, high reward projects and the creation of cross functional/organisational teams.